BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25518882)

  • 1. The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy.
    Su S; Hu Y; Ouyang W; Ma Z; Lu B; Li Q; Li H; Wang Z; Wang Y
    Radiat Oncol; 2014 Dec; 9():290. PubMed ID: 25518882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study.
    Su SF; Hu YX; Ouyang WW; Lu B; Ma Z; Li QS; Li HQ; Geng YC
    BMC Cancer; 2013 Oct; 13():474. PubMed ID: 24118842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
    Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
    BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
    Ouyang WW; Su SF; Ma Z; Hu YX; Lu B; Li QS; Geng YC; Li HQ
    Radiat Oncol; 2014 Jun; 9():147. PubMed ID: 24962716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study.
    Ouyang WW; Su SF; Hu YX; Lu B; Ma Z; Li QS; Li HQ; Geng YC
    BMC Cancer; 2014 Jul; 14():491. PubMed ID: 25001175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer.
    Ball D; Mitchell A; Giroux D; Rami-Porta R;
    J Thorac Oncol; 2013 Mar; 8(3):315-21. PubMed ID: 23334092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
    Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
    Topkan E; Parlak C; Kotek A; Yuksel O; Cengiz M; Ozsahin M; Pehlivan B
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1264-71. PubMed ID: 22172902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer.
    Koshy M; Malik R; Mahmood U; Rusthoven CG; Sher DJ
    Pract Radiat Oncol; 2015; 5(6):374-82. PubMed ID: 26412340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
    Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy.
    Oh D; Ahn YC; Park HC; Lim DH; Noh JM; Cho WK; Pyo H
    Oncotarget; 2017 May; 8(22):35700-35706. PubMed ID: 28415687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
    Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N
    Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
    Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
    Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach.
    Parlak C; Mertsoylu H; Güler OC; Onal C; Topkan E
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):885-91. PubMed ID: 24495594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy.
    Topkan E; Yildirim BA; Guler OC; Parlak C; Pehlivan B; Selek U
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):774-80. PubMed ID: 25752391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.